Respiratory Disorders

Respiratory Disorders

Introduction

·       The respiratory system ensures the exchange of gases—oxygen intake and carbon dioxide elimination—essential for cellular metabolism and survival.

·       Any disruption in this process leads to respiratory disorders, which may affect airways, alveoli, interstitium, or the pleura.

·       Respiratory disorders can be acute or chronic, infectious or non-infectious, and may cause significant morbidity and mortality.

·       Key pathological mechanisms include airway obstruction, parenchymal inflammation or destruction, impaired gas exchange, and respiratory muscle fatigue.

·       Understanding common respiratory disorders is essential for prevention, early diagnosis, and management.

Chronic Obstructive Pulmonary Disease (COPD)

Definition

A chronic, progressive, and largely irreversible airflow limitation characterized by chronic bronchitis and emphysema, often associated with long-term exposure to noxious particles (e.g., cigarette smoke).

Etiology / Risk Factors

  • Smoking (primary risk factor)
  • Occupational dust and chemicals
  • Air pollution
  • Alpha-1 antitrypsin deficiency (genetic)
  • Aging

Pathophysiology

  • Chronic bronchitis: inflammation of bronchi → mucus hypersecretion → airway narrowing.
  • Emphysema: destruction of alveolar walls → reduced surface area for gas exchange.
  • Progressive airflow limitation → hypoxia and hypercapnia.

Clinical Features

  • Chronic productive cough (especially in morning)
  • Dyspnea on exertion → later at rest
  • Wheezing, chest tightness
  • Cyanosis ("blue bloater") or barrel chest ("pink puffer")
  • Fatigue, weight loss

Diagnosis

  • Spirometry: ↓ FEV1/FVC ratio (<70%)
  • Chest X-ray: hyperinflated lungs, flattened diaphragm
  • ABG: hypoxemia, hypercapnia
  • Blood test: alpha-1 antitrypsin levels (if young, non-smoker)

Complications

  • Pulmonary hypertension
  • Cor pulmonale (right heart failure)
  • Respiratory failure

Management

  • Smoking cessation (most important)
  • Bronchodilators (β2-agonists, anticholinergics)
  • Inhaled corticosteroids
  • Oxygen therapy (long-term in hypoxemia)
  • Pulmonary rehabilitation, breathing exercises
  • In severe cases: lung volume reduction surgery or transplantation

Pneumonia

Definition

An acute infection of the lung parenchyma (alveoli, interstitium) caused by bacteria, viruses, fungi, or aspiration.

Types

  • Community-acquired pneumonia (CAP)
  • Hospital-acquired pneumonia (HAP)
  • Aspiration pneumonia
  • Opportunistic pneumonia (immunocompromised patients)

Common Etiological Agents

  • Bacterial: Streptococcus pneumoniae, Klebsiella, Staphylococcus aureus, Pseudomonas
  • Viral: Influenza, RSV, SARS-CoV-2
  • Fungal: Pneumocystis jirovecii, Histoplasma

Pathophysiology

  • Microorganisms reach alveoli → inflammation → alveolar filling with exudate → impaired oxygen diffusion.

Clinical Features

  • Fever, chills
  • Productive cough (purulent or rust-colored sputum)
  • Dyspnea, pleuritic chest pain
  • Crackles, bronchial breath sounds
  • Fatigue, confusion (elderly)

Diagnosis

  • Chest X-ray: lobar or patchy consolidation
  • Sputum culture, blood culture
  • CBC: leukocytosis
  • Pulse oximetry / ABG

Complications

  • Lung abscess
  • Pleural effusion, empyema
  • Sepsis, septic shock

Management

  • Antibiotics (empirical, then culture-guided)
  • Antivirals (if viral cause suspected, e.g., influenza)
  • Oxygen therapy, fluids, analgesics
  • Vaccination for prevention (Pneumococcal, Influenza)

Tuberculosis (TB)

Definition

A chronic infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but can involve other organs.

Risk Factors

  • Close contact with TB patients
  • HIV infection, immunosuppression
  • Malnutrition, diabetes
  • Overcrowding, poverty

Pathophysiology

  • Inhalation of droplet nuclei → bacilli reach alveoli → engulfed by macrophages → granuloma formation (Ghon complex).
  • Reactivation TB occurs when immunity is low.

Clinical Features

  • Chronic cough (>2 weeks), hemoptysis
  • Night sweats, fever, weight loss, fatigue
  • Chest pain, breathlessness

Diagnosis

  • Sputum smear (Ziehl-Neelsen stain, AFB test)
  • Culture (Löwenstein–Jensen medium)
  • GeneXpert / PCR
  • Chest X-ray: cavitary lesions, infiltrates
  • Mantoux test (screening)

Complications

  • Miliary TB
  • Pleural effusion, empyema
  • Fibrosis, bronchiectasis
  • MDR-TB (drug resistance)

Management

  • First-line anti-TB drugs (6-month regimen):
    2 months HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol) + 4 months HR (Isoniazid, Rifampicin)
  • DOTS (Directly Observed Treatment, Short-course)
  • MDR-TB: second-line drugs (e.g., fluoroquinolones, aminoglycosides)

Lung Infections (Other than TB & Pneumonia)

Includes viral, fungal, parasitic, and atypical bacterial infections.

Examples

  • Viral: Influenza, RSV, COVID-19
  • Fungal: Aspergillosis, Histoplasmosis, Cryptococcus
  • Atypical bacteria: Mycoplasma pneumoniae, Chlamydia pneumoniae

Features

  • Fever, cough, malaise
  • Wheezing, dyspnea
  • Sometimes hemoptysis (fungal infections)

Diagnosis

  • Sputum culture, viral PCR
  • Chest imaging (cavitations, nodules, diffuse infiltrates)
  • Serology (fungal infections)

Management

  • Antivirals (oseltamivir for influenza)
  • Antifungals (amphotericin B, voriconazole)
  • Supportive oxygen, fluids, antibiotics (for secondary infections)

Acute Respiratory Distress Syndrome (ARDS)

Definition

A severe, life-threatening condition with diffuse alveolar damage leading to non-cardiogenic pulmonary edema and acute hypoxemic respiratory failure.

Causes

  • Sepsis (most common)
  • Trauma, burns
  • Aspiration, pneumonia
  • Pancreatitis
  • COVID-19

Pathophysiology

  • Injury to alveolar-capillary membrane → increased permeability → fluid leakage into alveoli → decreased surfactant → stiff lungs → refractory hypoxemia.

Clinical Features

  • Acute onset severe dyspnea
  • Hypoxemia unresponsive to oxygen therapy
  • Diffuse crackles, cyanosis
  • Respiratory distress, tachypnea

Diagnosis

  • CXR: bilateral “white-out” infiltrates
  • ABG: severe hypoxemia (PaO2/FiO2 < 200)
  • Rule out cardiogenic pulmonary edema (normal cardiac function)

Management

  • Mechanical ventilation with low tidal volume
  • PEEP (positive end-expiratory pressure)
  • Treat underlying cause (sepsis, trauma, pneumonia)
  • Prone positioning, ECMO (in refractory cases)

Respiratory Failure

Definition

Failure of the lungs to maintain adequate oxygenation (PaO2 < 60 mmHg) and/or CO2 elimination (PaCO2 > 50 mmHg).

Types

  • Type I (Hypoxemic): ↓ PaO2 (ARDS, pneumonia, pulmonary edema)
  • Type II (Hypercapnic): ↑ PaCO2 (COPD, drug overdose, neuromuscular disorders)

Clinical Features

  • Dyspnea, cyanosis
  • Restlessness, confusion, headache
  • Tachypnea or bradypnea (in severe cases)
  • Signs of underlying cause

Diagnosis

  • ABG analysis
  • Pulse oximetry
  • CXR / CT for underlying disease

Management

  • Oxygen therapy (careful in COPD)
  • Mechanical ventilation if severe
  • Treat underlying cause (infection, obstruction, drug overdose)
  • Bronchodilators, corticosteroids (if obstructive)

Asthma

Definition

A chronic inflammatory disorder of the airways characterized by reversible airflow obstruction and bronchial hyperresponsiveness.

Triggers

  • Allergens (dust, pollen, animal dander)
  • Exercise, cold air
  • Respiratory infections
  • Drugs (aspirin, beta-blockers)
  • Occupational irritants

Pathophysiology

  • Exposure to trigger → immune response → mast cell degranulation → histamine, leukotrienes → bronchoconstriction + airway inflammation + mucus production.

Clinical Features

  • Episodic wheezing, breathlessness
  • Cough, especially at night or early morning
  • Chest tightness
  • Prolonged expiration
  • In severe attack: silent chest, cyanosis (status asthmaticus)

Diagnosis

  • Spirometry: reversible ↓ FEV1/FVC, improved after bronchodilator
  • Peak expiratory flow rate monitoring
  • Allergy tests (IgE, skin prick)

Complications

  • Status asthmaticus (life-threatening)
  • Respiratory failure
  • Chronic airway remodeling

Management

  • Acute attack: short-acting β2-agonist (salbutamol), oxygen
  • Long-term control:
    • Inhaled corticosteroids (first-line)
    • Long-acting β2-agonists (LABA)
    • Leukotriene receptor antagonists
  • Avoidance of triggers
  • Patient education and inhaler technique training

Video Description

·        Don’t forget to do these things if you get benefitted from this article

·        Visit our Let’s contribute page https://keedainformation.blogspot.com/p/lets-contribute.html

·        Follow our page

·        Like & comment on our post

·        


 

 

 

Comments

Popular posts from this blog

Bio Medical Waste Management

Basic concepts of Pharmacology

Introduction, History, Growth & Evolution of Management